Onconetix Inc. (ONCO)
0.06
-0.00 (-3.69%)
At close: Apr 14, 2025, 12:52 PM
-3.69% (1D)
| Bid | 0.06 |
| Market Cap | 930.89K |
| Revenue (ttm) | 1.87M |
| Net Income (ttm) | -51.6M |
| EPS (ttm) | -87.25 |
| PE Ratio (ttm) | n/a |
| Forward PE | -0.71 |
| Analyst | n/a |
| Ask | 0.06 |
| Volume | 1,492,402 |
| Avg. Volume (20D) | 9,786,291 |
| Open | 0.06 |
| Previous Close | 0.06 |
| Day's Range | 0.06 - 0.07 |
| 52-Week Range | 0.05 - 21.40 |
| Beta | 3.52 |
About ONCO
Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 18, 2022
Employees 12
Stock Exchange NASDAQ
Ticker Symbol ONCO
Website https://onconetix.gcs-web.com
2 months ago
+34.06%
Onconetix shares are trading higher. The company a...
Unlock content with
Pro Subscription
4 months ago
-13.92%
Onconetix shares are trading lower after the company announced it received a Nasdaq notice for a late quarterly report and subsequent filing.
